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Abstract
 . Present-day catarrhines old world monkeys and hominoids lack Gal a1-3 Gal b 1-4 GlcNAc-R structures a-galactosyl
.  .  .epitopes and produce the corresponding anti-galactosyl antibodies anti-gal , while platyrrhines new world monkeys and
non-primate mammals possess a-galactosyl epitopes and lack anti-gal. Anti-gal is shown to inhibit Plasmodium falciparum
growth in culture in a concentration dependent manner, probably by binding to a-galactosyl epitopes on merozoite surface
molecules and causing complement mediated damage. A P. falciparum-like malaria parasite may therefore have selected
for the inactivation of an a1-3 galactosyl transferase in catarrhines. The implications of the results for the development of
clinical immunity to falciparum malaria are briefly discussed.
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1. Introduction
Malaria due to Plasmodium falciparum has ex-
erted selective pressure on human populations at the
w xlevel of globin 1 , major histocompatibility complex
 . w xMHC 2,3 and glucose 6-phosphate dehydrogenase
w x4 genes. The MHC class I antigen HLA-Bw53,
which is common among west and central Africans
but rare in caucasians and orientals, affords 40%
Abbreviations: anti-gal, anti-galactosyl antibodies; a-galacto-
syl epitope, Gal a1-3 Gal b 1-4 GlcNAC-R; a1,3 GT, a1,3
galactosyl transferase; MHC, major histocompatibility complex;
mya, million years ago; rbc, red blood cells.
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protection against cerebral malaria or severe malaria-
w xinduced anaemia 2 . The molecular basis for this
protection has been ascribed to HLA-Bw53 restricted
recognition of an epitope on a P. falciparum liver-
w xstage specific antigen by cytotoxic T cells 3 . Gal
a1-3 Gal b 1-4 GlcNAc-R structures termed a-
.galactosyl epitopes are absent in old world primates
 .including man the catarrhines but common in gly-
colipids and glycoproteins of new world monkeys
 . w xthe platyrrhines and non-primate mammals 5,6 .
Correspondingly, natural antibodies to the a-
 .galactosyl epitopes termed anti-gal are present in
catarrhines and absent in platyrrhines and non-primate
ww xmammals 6 , Ramasamy, R. and Rajakaruna, R.,
xunpublished data . Inactivation of an a1-3 galactosyl
 .transferase a1,3 GT in the Golgi of catarrhines is
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w xresponsible for the difference 7 and it has been
w xspeculated that a pathogen 7 , possibly a malaria
w xparasite 8,9 , may have been the cause. We provide
evidence that a P. falciparum-like parasite could
have exerted the necessary selective pressure to inac-
tivate a1,3 GT. A preliminary report of this work
was presented at the Biochemical SocietyrBritish
Society for Immunology joint congress in Harrogate,
UK in December 1996.
2. Materials and methods
2.1. Preparation of anti-gal antibodies and anti-gal
deficient serum
Thirty ml AB serum from donors with no known
malaria exposure and 7 ml pools of sera of unknown
.blood groups from malaria-endemic Weheragala vil-
lage with antibodies to P. falciparum merozoite sur-
w xface proteins 10 were sequentially passed through a
2 ml control silica column and a 2 ml Gala1-3
Galb 1-4 GlcNAc-R Synsorb column Chembiomed,
.Edmonton, Canada for affinity purifying anti-gal
antibodies. The columns were washed extensively in
 .0.01 M phosphate buffered saline, pH 7.2 PBS .
Proteins bound to the control silica and Gal a1-3 Gal
b 1-4 GlcNAc-R columns were then eluted with 3 ml
0.1 M glycine-HCl buffer, pH 3.0 to yield the control
w xand anti-gal eluates respectively 11,12 . The two
parallel eluates were neutralised with 0.1 M NaOH,
dialysed extensively against the same batch of RPMI
1640 and sterilised by filtration through 0.22 mm
filters. Anti-gal activity in the two eluates were deter-
mined by direct haemagglutination of 5% haematocrit
w xrabbit red blood cells 11 . Different preparations of
anti-gal and control eluates had haemagglutination
titres of 32–2000 and 2–64 respectively, with the
anti-gal titre being always greater than that of the
corresponding control. Analysis of anti-gal by SDS-
PAGE revealed mainly IgG in anti-gal with traces of
IgM and other serum proteins and a total protein
concentration of 32–172 mg mly1 in different prepa-
rations. Control eluates contained mainly IgM with
traces of IgG and other serum proteins. AB serum
that had been sequentially passed through the silica
and oligosaccharide columns was used as anti-gal
deficient serum for parasite cultures.
[3 ]2.2. H hypoxanthine incorporation assay for deter-
mining parasite growth inhibition
 .P. falciparum 3D7 isolate was routinely main-
 .tained in culture in 0q red cells rbc and RPMI
1640 supplemented with 10% ABq human serum,
22 mM Hepes, 24 mM sodium bicarbonate and 10
mg mly1 gentamicin in an atmosphere of 5% 0 , 5%2
w xCO , 90% N at 378C 13,14 . P. falciparum was2 2
adapted to grow in anti-gal deficient AB serum for
parasite growth-inhibition experiments. Late stage
parasites were obtained from cultures by gelatine
w xsedimentation 15 . For a given experiment, different
eluates in RPMI 1640 were used to prepare complete
medium containing 10% of the same anti-gal defi-
cient serum to which the parasites were culture-
adapted. Parasites at 0.5%–1.0% parasitaemia in dif-
ferent experiments were then added to the medium to
yield 5% haematocrit, and 100 ml aliquots dispensed
into sterile 96 well culture plates in 4–8 replicates
and incubated in an atmosphere of 5% CO , 95% air2
w3 xat 378C. Twenty four hours later, 5 mCi H hypo-
 .xanthine Amersham in 100 ml RPMI 1640 was
w xadded to each well as described 14 . At 48 h, the
cells were harvested onto Millipore glass fibre filters,
the DNA precipitated with ice-cold 5% trichloro-
acetic acid and washed in 70% ethanol, and radioac-
tivity in the DNA determined by liquid scintillation
counting.
2.3. Microscopic determination of parasite growth
inhibition
Late stage 3D7 parasites were cultured as de-
scribed above in the presence of anti-gal and control
column eluates isolated from immune serum from
w xanother malaria endemic village, Nikawehera 16 .
Smears of cultures were obtained at 24h and 48h
after initiation of culture, stained with Giemsa and
the proportions of different parasite stages deter-
mined by microscopy. The anti-gal used in this exper-
 .iment produced 41% inhibition P-0.001 when
compared to the corresponding control antibodies, in
w3 xa parallel H hypoxanthine incorporation assay.
2.4. Requirement for complement
An aliquot of the anti-gal deficient AB serum used
to grow parasites was heated to 568C for 30 min to
heat inactivate complement. Parallel cultures were
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then set up as described using the complement inacti-
vated and normal anti-gal deficient sera to each of
which were added the same preparation of anti-gal
and control antibodies.
3. Results
Anti-gal isolated from immune and non-immune
human sera inhibited the re-invasion and growth of
P. falciparum in cultures grown in AB serum de-
pleted of anti-gal. The results of two experiments
with seven different preparations of anti-gal are given
in Table 1. Pooling results from several experiments,
w3 xit was observed that anti-gal inhibited H hypo-
xanthine incorporation in 19 out of 22 tests when
compared to the corresponding controls. In 11 out of
19 tests the inhibitions were statistically significant at
PF0.05 by the t test.
Microscopic determination of the numbers of rings
and trophozoitesrschizonts present at 24 and 48 h
after adding antibodies to cultures i.e. upto one
.complete cycle of rbc invasion and growth indicated
that inhibition of merozoite invasion was primarily
 .responsible for this effect Fig. 1 . The binding of
anti-gal but not the control antibodies to P. falci-
parum merozoites was demonstrable by immunofluo-
rescence on acetone fixed late stage parasites
Ramasamy, R. and Rajakaruna, R., unpublished
.data .
Varying the concentration of anti-gal by serial
dilution of added antibodies in RPMI 1640 showed
that the anti-gal eluate inhibited parasite growth at
lower protein concentrations than the control eluate
 .Table 2 . In a related experiment, the addition of a
 .human IgG1rkappa myeloma protein Sigma, USA
at a concentration of 100 mg mly1 in RPMI 1640 did
w3 xnot significantly inhibit H hypoxanthine incorpora-
tion into parasites in comparison to the addition of
control eluate from immune serum at a protein con-
y1 centration of 88 mg ml 19 486"1490 vs 19 820
."2075 cpm"S.D. respectively .
Table 1
Inhibition of P. falciparum growth by anti-galactosyl antibodies
3 . w xAddition protein concn H hypoxanthine Inhibition P
incorporation
 .mean cpm"S.D.
Experiment 1
 .A i Control medium 9 450"316 – –
 .B i Control eluate from immune serum – pool A 9 991"395 – –
 .ii Anti-gal eluate from pool A 7 644"395 23% 0.002
 .C i Anti-gal eluate from immune serum –pool B 6 117"399 35% 0.0001
 .ii Anti-gal eluate from immune serum –pool C 6 894"1 403 27% 0.01
Experiment 2
y1 .  .A i Control eluate from immune serum –pool D 88 mg ml 35 961"2 800 – –
y1 .  .ii Anti-gal eluate from pool D 144 mg ml 26 696"2 275 17% 0.001
y1 .  .B i Control eluate from non-immune AB serum –pool E 64 mg ml 34 580"3 741 – –
y1 .  .ii Anti-gal eluate from pool E 160 mg ml 31 284"2 261 10% 0.05
y1 .  .C i Control eluate from immune serum –pool F 104 mg ml 39 813"2 127 – –
y1 .  .ii Anti-gal eluate from pool F 160 mg ml 34 613"596 13% 0.001
y1 .  .D i Control eluate from non-immune AB serum – pool G 72 mg ml 32 106"2 251 – –
 .  y1.ii Anti-gal eluate from pool G 120 mg ml 32 266"1 758 0% n.s.
w3 xThe effects of anti-gal and control eluates on P. falciparum growth determined by H hypoxanthine incorporation. Different pools of
w3 xsera used to prepare eluates are labelled A–G. Th immune sera were obtained from Weheragala village. The H hypoxanthine was used
at a specific activity of 6 GBq mmoly1 in Exp. 1 and at 200 GBq mmoly1 in Exp. 2 and subsequent experiments. Protein concentrations
 . w3 xof eluates are given where available. Significance P of the differences between H hypoxanthine incorporated in the presence of
anti-gal and the corresponding control eluates were determined by Student’s t test, except in 1C where anti-gal treatment was compared
 .to parasites cultured in RPMI 1640 medium containing anti-gal deficient serum without added antibodies control medium 1A . Data
represent mean"standard deviation for four or more determinations. n.s.snot significant, P)0.05.
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Table 2
Effect of anti-gal concentration on inhibition of P. falciparum growth
3 . w xAntibody protein concn H hypoxanthine Inhibition P
incorporation
 .mean cpm"S.D.
y1 .1. Anti-gal from immune serum – pool H 108 mg ml 49 821"2200 9.5% 0.001
y1 .2. Anti-gal from immune serum – pool H 10.8 mg ml 52 052"3169 5.5% 0.05
y1 .3. Anti-gal from immune serum – pool H 1.1 mg ml 54 256"2416 1.5% n.s.
y1 .4. Control eluate from immune serum – pool H 88 mg ml 55 059"998 –
 .The effect of 10-fold dilutions of anti-gal immune Weheragala sera pool H on P. falciparum growth. The anti-gal was diluted in fresh
RPMI 1640 and 100 ml aliquots of the antibodies were added to cultures. Data represent mean"standard deviation of eight replicate
cultures. Statistical analyses were done as described in Table 1.
Table 3
Role of complement in anti-gal mediated inhibition of parasite growth
3 . w xAddition protein concn Serum H hypoxanthine Inhibition P
incorporation
 .mean cpm"S.D.
y1 .1. Anti-gal from immune serum – pool H 108 mg ml Normal 51 639"4 191 17% 0.001
y1 .2. Control eluate from immune serum – pool H 88 mg ml Normal 62 158"3 776 –
y1 .3. Anti-gal from immune serum – pool H 108 mg ml Heat inactivated 65 563"3 756 0% n.s.
y1 .4. Control eluate from immune serum – pool H 88 mg ml Heat inactivated 65 280"1 756 –
The effect of heat inactivating complement on anti-gal mediated inhibition of parasite growth. The anti-gal was prepared from immune
Weheragala serum. Data represent mean"S.D. of eight replicate cultures. Statistical analyses were done as described in Table 1 for
differences between samples 1 vs. 2 and 3 vs. 4.
 .  .Fig. 1. Effect of control A and anti-gal B eluates from
immune Nikawehera serum on growth of P. falciparum deter-
mined from Giemsa stained films.
Inactivating complement components by heating
the anti-gal deficient serum used for culturing the
parasites, abolished growth inhibition mediated by
 .added anti-gal Table 3 .
4. Discussion
Terminal a-galactose residues are present on the
w x w x185 kDa 17 and 45 kDa 18 P. falciparum mero-
zoite surface proteins in O-linked oligosaccharides
w x19 or glycophosphatidyl inositol membrane anchors
w x18 . The binding of Bandeiraea simplicifolia IB4
lectin to parasite membranes shows that the terminal
w xgalactose residues are present in a1-3 linkages 17 .
w x w xAntibodies in non-immune 8 and immune 17,20
human sera have been previously shown to recognise
a-galactosyl epitopes in P. falciparum by ELISA or
immunofluorescence. Indeed, the binding of natural
antibodies in non-immune human sera to P. falci-
parum can be inhibited by 0.5 M a-methyl galacto-
w xside 8 . The data presented here show that the bind-
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ing of anti-gal to merozoite surface proteins inhibits
parasite growth through complement mediated lysis
of merozoites. It is probable that the in vitro growth
inhibition assay underestimates the capacity of anti-
bodies to inhibit parasite growth in vivo. Merozoites
probably traverse greater distances between rbc in
vivo than in the settled layer of rbc in 96 well plates
and can therefore be exposed to antibodies for a
longer time. Complement mediated lysis is likely to
be more efficient in plasma in vivo than in culture
medium containing 10% serum in vitro. There is also
evidence that monocytes, macrophages and neu-
trophils, that were not present in the cultures, can
promote antibody-dependent, cell-mediated immunity
w xin vivo 21 .
The degree of growth inhibition varied between
different anti-gal preparations of similar protein con-
centration. Differential loss of antibody activity dur-
ing preparation and storage and differences in IgG
isotype composition and consequently complement
fixing ability, may be some of the factors responsible
for this variability. The maximum growth inhibition
observed with anti-gal is less than the 96% inhibition
reported with 121 mg mly1 of an IgG monoclonal
antibody directed against a peptide epitope on the
w x45kDa merozoite surface antigen 22 . The difference
may partly reflect higher affinity and faster binding
of anti-peptide antibodies to merozoites. Since mero-
zoites invade rbc rapidly, the rate of antibody binding
is likely to a critical factor in invasion inhibition. It is
possible that a proportion of merozoites that express
fewer a-galactosyl epitopes avoid complement medi-
ated lysis and that this process can give rise to P.
falciparum mutants lacking a-galactosyl epitopes.
However the presence of a-galactosyl epitopes in
w x w x w xFVO 17 , Honduras 1 8,17 , FC27 8 and 3D7
isolates P. falciparum suggests that the correspond-
ing oligosaccharide structures may be conserved be-
cause they have a vital function in parasite biology.
Analysis of gene sequences indicates that inactiva-
tion of a1,3 GT occurred as two independent events
in the two groups of catarrhines viz. old world mon-
keys and hominoids, no more than 17–25 million
 . w xyears ago mya 7 . Plasmodium genus is about 150
w xmillion years old 23 . Analysis of the sequences of
small subunit ribosomal RNA and circumsporozoite
protein genes show that P. falciparum is closely
related to a chimpanzee parasite P. reichenowi
w x24,25 . These two malaria parasites form a clade that
is more closely related to avian and reptilian malaria
parasites P. gallinaceum, P. lophurae and P. mexi-
. canum than to other primate and human e.g. P.
.knowlesi, P. ˝i˝ax, P. malariae and P. o˝ale or
 . w xmurine e.g. P. berghei parasites 23–25 . Catar-
w xrhines diverged from platyrrhines 30–35 mya 26 .
We postulate that during the Oligocene or early
Miocene, a P. falciparum-like, non-primate prob-
.ably avian or reptilian parasite adapted itself to
infect primates in the old world which later led to the
inactivation of a1,3 GT in the hosts. The driving
force for inactivation of a1,3 GT may have been the
ability to produce antibodies reactive with a-
galactosyl epitopes of the parasite which then con-
ferred significant protection against falciparum-like
malaria without inducing autoimmunity. It is not
possible to extrapolate easily from human anti-gal
inhibition of P. falciparum growth in cultures to the
selective advantage afforded by anti-gal in early
catarrhines, which may have been considerably
greater. Since P. falciparum was probably introduced
w xinto the Americas after Christopher Columbus 27 ,
there would have been no similar selective pressure
to inactivate a1,3 GT in platyrrhines. A prediction of
this hypothesis viz. that P. falciparum infects
platyrrhines more readily than old world monkeys, is
w xalready established 28 . Natural anti-gal in non-im-
mune humans, like antibodies to blood group A and
B antigens, are probably produced as a result of
stimulation of the immune system by cross-reactive
epitopes on the cell walls of common intestinal bacte-
w xria 29 . There is no evidence at present to support an
alternative possibility that selection due to a common
bacterial pathogen prevalent in the old world, but not
in the new world, could have caused the inactivation
of a1,3 GT in catarrhines.
The natural anti-gal clearly provides only partial
protection against human falciparum malaria. How-
ever partial protection against malaria afforded by
MHC molecules have produced significant genetic
w xchanges in human populations 2,3 . The relevance of
anti-gal to strain transcending clinical immunity to
falciparum malaria observed in adults living in highly
malaria-endemic areas, and the detailed structure of
parasite a-galactosyl epitopes and its relationship to
the specificity of human anti-gal need to be deter-
mined. In this context it is relevant to note that higher
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levels of anti-gal have been reported in persons living
in malaria-endemic areas and in patients with acute
w xfalciparum malaria 30 . The human blood group B
 .epitope has the structure Gal a1-3 Fuc a1-2 Gal
b 1-4 GlcNAc-R and a subset of anti-B antibodies are
w xreported to have anti-gal activity 31 . Hence the
possibility that A and O blood groups afford some
degree of protection against falciparum malaria re-
quires investigation.
P. falciparum proteins are presently being investi-
gated as the basis of a vaccine against falciparum
malaria. Our results suggest that oligosaccharide moi-
eties of the parasite may also be useful for this
purpose.
Acknowledgements
We are grateful to Dr. U. Galili for the Synsorb
columns and V. Udawatte for secretarial assistance.
References
w x  .1 Allison, A.C. 1954 Trans. R. Soc. Trop. Med. Hyg. 48,
312–318.
w x2 Hill, A.V.S., Allsopp, C.E.M., Kwiatkowski, D., Anstey,
N.M., Twumasi, P., Rowe, P.A., Bennett, S., Brewster, D.,
 .McMichael, A.J. and Greenwood, B.M. 1991 Nature 352,
595–600.
w x3 Hill, A.V.S., Elvin, J., Willis, A.C., Aidoo, M., Allsopp,
C.E.M., Goth., F.M., Gao, X.M., Takiguchi, M., Green-
wood, B.M., Townsend, A.R.M., McMichael, A.J. and
 .Whittle, H.C. 1992 Nature 360, 434–439.
w x4 Ruwende, C., Khoo, S.C., Snow, R.W., Yates, S.N.R.,
Kwiatkowski, D., Gupta, S., Warn, P., Allsopp, C.E.M.,
Gilbert, S.C., Peschu, N., Newbold, C.I., Greenwood, B.M.,
 .Marsh, K. and Hill, A.V.S. 1995 Nature 376, 246–249.
w x  .5 Spiro, R.G. and Bhoyroo, V.D. 1984 J. Biol. Chem. 259,
9858–9866.
w x6 Galili, U., Shohet, S.B., Kobrin, E., Stults, C.L.M. and
 .Macher, B.A. 1988 J. Biol. Chem. 263, 17755–17762.
w x  .7 Galili, U. and Swanson, K. 1991 Proc. Natl. Acad. Sci.
USA 88, 7401–7404.
w x  .8 Ramasamy, R. 1988 Indian J. Med. Res. 87, 584–593.
w x  .9 Ramasamy, R. 1994 Immunol. Today 15, 140.
w x  .10 Ramasamy, R., Nagendran, K. and Ramasamy, M.S. 1994
Am. J. Trop. Med. Hyg. 50, 537–547.
w x11 Galili, U., Rachmilewitz, E.A. Peleg, A. and Fechner, I
 .1984 J. Exp. Med. 160, 1519–1531.
w x12 Galili, U., Clark, M.R., Shohet, S.B., Buehler, J. and Macher,
 .B.A. 1987 Proc. Natl. Acad. Sci. USA 84, 1369–1373.
w x  .13 Trager, W. and Jensen, J.B. 1976 Science 193, 673–675.
w x14 Ramasamy, R., Kanagaratnam, R., Misiura, K., Rebowski,
 .G., Amerakoon, R. and Stec, W. 1996 . Biochem. Biophys.
Res. Commun. 218, 930–933.
w x  .15 Jensen, J.B. 1994 Am. J. Trop. Med. Hyg. 27, 1274–1276.
w x  .16 Ramasamy, R., Nagendran, K. and Ramasamy, M.S. 1995 .
Indian J. Med. Res. 101, 66–74.
w x  .17 Ramasamy, R. and Reese, R.T. 1986 Mol. Biochem. Para-
sitol. 19, 91–101.
w x  .18 Ramasamy, R. 1987 Immunol. Cell. Biol. 65, 419–424.
w x19 Nasir-ud-Din, Drager-Dayal, R., Decrind, C., Hu, B.H., Del
 .Giudice, G. and Hoessli, D. 1992 Biochem. Int. 27, 58–64.
w x  .20 Ramasamy, R. and Reese, R.T. 1985 J. Immunol. 134,
1952–1955.
w x  .21 Druilhe, P. and Perignon, J.L. 1994 Immunol. Lett. 41,
115–120.
w x22 Epping, R., Jelacic, S., Ingram, L., Upcroft, J., Ramasamy,
 .R., Bushell, G. and Geysen, H.M. 1988 Mol. Biochem.
Parasitol. 28, 1–10.
w x  .23 Escalante, A.A., Barrio, E. and Ayala, F.J. 1995 Mol.
Biol. Evol. 12, 616–626.
w x  .24 Escalante, A.A. and Ayala, F.J. 1994 Proc. Natl. Acad.
Sci. USA 91, 11373–11377.
w x  .25 Waters, A.P., Higgins, D.G. and McCutchan, T.F. 1991
Proc. Natl. Acad. Sci. USA 88, 3140–3144.
w x  .26 Fleagle, J.G. 1988 Primate Adaptation and Evolution.
Academic Press, London.
w x  .27 Bruce-Chwatt, L.J. 1965 Bull. WHO 32, 363–387.
w x  .28 Collins, W.E. 1992 Mem. Inst. Oswaldo. Cruz. 87, 401–
406.
w x29 Galili, U., Mandrell, R.E., Hamadeh, R.M., Shohet, S.B.
 .and Griffiss, J.M. 1988 Infect. Immun. 56, 1730–1737.
w x  .30 Ravindran, B., Satapathy, A.K. and Das, M.K. 1988 .
Immunol. Lett. 19, 137–142.
w x  .31 Galili, U. 1988 . Transfus. Med. Rev. 2, 112–121.
